Glaxosmithkline Pharmaceuticals
Glaxosmithkline Pharmaceuticals Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Glaxosmithkline Pharmaceuticals Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Glaxosmithkline Pharmaceuticals Ltd trades at a P/E of 34.67× and P/B of 15.85×.
Valuation
Profitability
Growth
Financial Health
Glaxosmithkline Pharmaceuticals Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Glaxosmithkline Pharmaceuticals Ltd, switchable between annual and quarterly views, consolidated or standalone.
Glaxosmithkline Pharmaceuticals Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹35,914.08 Cr and reported EPS of ₹61.20.
| Period | 2018 | 2019 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2,896 | 3,128 | 1,670 | 3,224 | 3,199 | 3,278 | 1,662 | 3,252 | 3,454 | 1,825 | 3,749 | 3,822 |
| Other Income | 55 | 102 | 47 | 79 | 111 | 76 | 50 | 101 | 123 | 70 | 146 | 145 |
| Total Income | 2,950 | 3,230 | 1,717 | 3,303 | 3,309 | 3,354 | 1,712 | 3,352 | 3,576 | 1,896 | 3,895 | 3,967 |
| Cost of Goods Sold (COGS) | 1,241 | 1,358 | 701 | 1,308 | 1,313 | 1,356 | 652 | 1,285 | 1,335 | 680 | 1,391 | 1,351 |
| Gross Profit | 1,654 | 1,770 | 969 | 1,917 | 1,886 | 1,922 | 1,010 | 1,967 | 2,119 | 1,146 | 2,358 | 2,471 |
| +Operating Expenses | 1,149 | 1,169 | 610 | 1,259 | 1,191 | 1,160 | 604 | 1,163 | 1,210 | 593 | 1,181 | 1,161 |
| EBITDA | 506 | 601 | 359 | 657 | 695 | 762 | 406 | 804 | 909 | 552 | 1,177 | 1,309 |
| +Non-Operating Expenses | 56 | 78 | 445 | -252 | -90 | 82 | 33 | 67 | -72 | 39 | 73 | 90 |
| Profit Before Tax (PBT) | 540 | 683 | 764 | 306 | 551 | 779 | 422 | 836 | 816 | 593 | 1,260 | 1,406 |
| +Tax Expense | 189 | 237 | 147 | 213 | 192 | 398 | 113 | 229 | 226 | 158 | 332 | 370 |
| Profit After Tax (PAT) | 351 | 445 | 616 | 93 | 358 | 381 | 313 | 611 | 590 | 435 | 928 | 1,036 |
| Earnings Per Share (EPS) | 20.70 | 26.29 | 36.38 | 5.50 | 21.14 | 100.04 | 18.46 | 36.05 | 34.83 | 25.67 | 54.75 | 61.15 |
| Diluted Shares Outstanding (Nos.) | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| +Additional Disclosures | 3,675 | 3,929 | 2,053 | 3,960 | 3,897 | 5,255 | 1,948 | 3,797 | 3,947 | 1,987 | 4,028 | 3,925 |
| Sales Growth % | — | 8.03 | -46.61 | 93.08 | -0.79 | 2.47 | -49.30 | 95.65 | 6.21 | -47.15 | 105.39 | 1.93 |
| YoY Sales Growth % | — | 8.03 | — | 3.08 | -0.79 | 2.47 | — | -0.80 | 6.21 | — | 8.56 | 1.93 |
| Material Cost % | 18 | 22 | 16 | 15 | 15 | 19 | 17 | 13 | 16 | 16 | 13 | 11 |
| Employee Cost % | 18 | 17 | 17 | 19 | 19 | 19 | 18 | 18 | 18 | 17 | 15 | 16 |
| Other Cost % | 22 | 20 | 19 | 20 | 18 | 17 | 19 | 17 | 17 | 16 | 16 | 15 |
| OPM % | 17 | 19 | 22 | 20 | 22 | 23 | 24 | 25 | 26 | 30 | 31 | 34 |
| Tax % | 35 | 35 | 19 | 70 | 35 | 51 | 27 | 27 | 28 | 27 | 26 | 26 |
| Profit Growth % | — | 26.99 | — | -79.07 | 284.28 | 6.32 | — | 60.38 | -3.39 | — | 57.23 | 11.69 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 468 | 552 | 318 | 575 | 616 | 694 | 374 | 739 | 839 | 519 | 1,111 | 1,243 |
Glaxosmithkline Pharmaceuticals segment analysis: revenue and profit mix.
Disclosed business segments at Glaxosmithkline Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.
Glaxosmithkline Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Glaxosmithkline Pharmaceuticals Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Glaxosmithkline Pharmaceuticals Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Glaxosmithkline Pharmaceuticals Ltd's investment case rests on 7 positive markers and 8 flagged concerns drawn from the latest reported filings.
What you're getting.
Glaxo boasts a robust Return on Equity (ROE) of 46.90% and Return on Capital Employed (ROCE) of 63.20%, significantly above industry averages. This highlights efficient capital utilization and superior profitability, showcasing strong operational performance.
Glaxo maintains a remarkably low debt-to-equity ratio of 0.01, signifying a very strong financial position with minimal reliance on external borrowing. This robust balance sheet provides significant stability and resilience against economic downturns.
The substantial promoter holding of 75% indicates strong management confidence and a long-term commitment to the company's vision. This stable shareholding structure minimizes hostile takeover risks, aligning management interests with shareholder value creation.
Glaxo reported a healthy quarterly profit growth of 12.40%, demonstrating consistent profitability and effective cost management. This positive trend in net profit after tax (PAT) indicates strong operational performance and potential for sustained earnings.
The broader Pharmaceuticals and Healthcare sector offers significant growth potential due to increasing global healthcare expenditure, an aging population, and continuous innovation in drug discovery. Glaxo is well-positioned to capitalize on these favorable industry trends.
What can break it.
Glaxo's Price-to-Earnings (P/E) ratio of 47.10 is relatively high compared to many industry peers, suggesting potential overvaluation. Investors should carefully assess this metric, considering the possibility of future price corrections and lower returns.
The company experienced a slight decline in quarterly sales, with a variance of -1.16%. This negative sales growth could indicate challenges in market demand or increased competition, warranting close monitoring for sustained revenue generation.
Glaxo's stock has shown recent volatility, declining by over 5% in the last five trading days. This short-term price fluctuation presents a risk for investors seeking stability and consistent returns, requiring careful consideration of risk tolerance.
The increase in public shareholding to 13.21% (as of 2024-12-01) warrants monitoring. A significant shift in public shareholding could potentially impact the company's control and long-term strategic direction, requiring investor vigilance.
Intense competition from both domestic and international pharmaceutical players poses a significant threat to market share and pricing power. Aggressive R&D by rivals could erode Glaxo's competitive edge in key therapeutic segments.
What would change my mind.
Trim if P/E re-rates above 45. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.97. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 44%. The operating engine is no longer compounding capital efficiently.
Glaxosmithkline Pharmaceuticals Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Glaxosmithkline Pharmaceuticals Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Glaxosmithkline Pharmaceuticals Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Glaxosmithkline Pharmaceuticals Ltd — derived from the live tape, not yesterday's close.
Glaxosmithkline Pharmaceuticals Ltd last traded at ₹2,121.5 with an intraday range of ₹2,088.1–₹2,131.9 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹2121.50| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2227.17 | +105.67 | +4.98% |
| R3 | 2183.37 | +61.87 | +2.92% |
| R2 | 2157.63 | +36.13 | +1.70% |
| R1 | 2139.57 | +18.07 | +0.85% |
| PIVOT | 2113.83 | -7.67 | -0.36% |
| CURRENT | 2121.50 | — | — |
| S1 | 2008.17 | -113.33 | -5.34% |
| S2 | 2051.97 | -69.53 | -3.28% |
| S3 | 2070.03 | -51.47 | -2.43% |
| S4 | 2095.77 | -25.73 | -1.21% |
GLAXO is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: 2101.1 ~ 2131.9
Trading Inside opening range
Glaxosmithkline Pharmaceuticals Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Glaxosmithkline Pharmaceuticals Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Glaxosmithkline Pharmaceuticals Ltd stood at 65.1% of traded volume, against a 20-day average of 59.6%.
Glaxosmithkline Pharmaceuticals announcements: results, concalls, ratings, M&A.
Filings Glaxosmithkline Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Glaxosmithkline Pharmaceuticals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 146 documents below.
Copy of Newspaper Publication
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Resignation of Director/KMP/SMP
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Resignation of Director/KMP/SMP
Copy of Newspaper Publication
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Cessation
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Cessation of Dr Simrat Sohal as Other of the company w.e.f. August 05,…
Analysts/Institutional Investor Meet/Con. Call Updates
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Transcript
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Glaxosmithkline Pharmaceuticals dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Glaxosmithkline Pharmaceuticals has declared, sequenced by announce and record date.
Glaxosmithkline Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Glaxosmithkline Pharmaceuticals Ltd: business, sector, key facts.
What Glaxosmithkline Pharmaceuticals Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Glaxosmithkline Pharmaceuticals Ltd operates in the Healthcare, listed as NSE: GLAXO, BSE: 500660.
GlaxoSmithKline Pharmaceuticals Limited (GSK) is a major pharmaceutical company with a global presence, including significant operations in India. Its core business revolves around the manufacturing, distribution, and trading of a wide range of pharmaceutical products. The company's history stretches back to 1924, with its current name adopted in 2001. GSK's headquarters are located in Mumbai, India.
A substantial portion of GSK's business focuses on vaccines. Their portfolio includes Infanrix Hexa (for multiple infant diseases), Synflorix (pneumococcal diseases), Havrix (Hepatitis A), Menveo (meningococcal disease), Boostrix (diphtheria, tetanus, and pertussis), Fluarix Tetra (influenza), Varilrix (varicella), and Shingrix (herpes zoster). This extensive vaccine range caters to various age groups and disease preventions, establishing GSK as a key player in the global vaccine market.
Beyond vaccines, GSK offers a diverse portfolio of specialty medicines. Key examples include NUCALA, used to treat severe eosinophilic conditions like asthma, and TRELEGY ELLIPTA, a treatment for chronic obstructive pulmonary disease (COPD). These specialty medications target specific, often chronic, conditions, reflecting GSK's commitment to developing advanced therapies.
GSK also provides a broad selection of general medicines. This includes antibiotics like AUGMENTIN and CEFTUM for bacterial infections, various formulations for mineral and vitamin deficiencies (CobadexCZS, CCM), pain relievers (CALPOL), treatments for hypothyroidism (ELTROXIN), skin creams and ointments (Flutivate, Tenovate, BETNOVATE, PHYSIOGEL, NEOSPORIN, T-BACT) addressing a wide range of dermatological needs. This segment underscores GSK's commitment to providing accessible and widely used treatments for common ailments.
In summary, GlaxoSmithKline Pharmaceuticals Limited operates across multiple sectors of the pharmaceutical industry, offering a comprehensive range of vaccines, specialty medicines targeting complex conditions, and a large selection of general medicines for everyday health concerns. This diversified approach positions GSK as a significant player in the global pharmaceutical market.
Questions investors ask about Glaxosmithkline Pharmaceuticals Ltd (GLAXO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Glaxosmithkline Pharmaceuticals Ltd (GLAXO)?
The current share price of Glaxosmithkline Pharmaceuticals Ltd (GLAXO) is ₹2,121.5. Today, the stock has gained by ₹18.30 (0.87%), trading in a range of ₹2,088.1 to ₹2,131.9. The stock opened at ₹2,116 with a trading volume of 3,57,494 shares.
02Is Glaxosmithkline Pharmaceuticals Ltd stock a good investment for long-term?
Glaxosmithkline Pharmaceuticals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹35,914.08 crores, P/E ratio of 34.67, ROE of 49.11%, and ROCE of 63.20%. The dividend yield stands at 2.71%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Glaxosmithkline Pharmaceuticals Ltd stock?
The 52-week high price of Glaxosmithkline Pharmaceuticals Ltd (GLAXO) is ₹0, while the 52-week low is ₹0. Currently trading at ₹2,121.5, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Glaxosmithkline Pharmaceuticals Ltd stock at the current price?
Whether to buy Glaxosmithkline Pharmaceuticals Ltd stock at ₹2,121.5 depends on multiple factors. The stock is currently trading with a P/E ratio of 34.67 and P/B ratio of 15.85. Today's performance shows a gain of 0.87%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Glaxosmithkline Pharmaceuticals Ltd and when is the next dividend?
Glaxosmithkline Pharmaceuticals Ltd offers a dividend yield of 2.71%, which means for every ₹100 invested at the current price of ₹2,121.5, you can expect to receive approximately ₹2.71 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd's key financial metrics include: P/E Ratio: 34.67, P/B Ratio: 15.85, ROE: 49.11%, ROCE: 63.20%, Dividend Yield: 2.71%, EPS: ₹61.20, Book Value: ₹133.85, and Debt-to-Equity: 1.47. The company's market cap stands at ₹35,914.08 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Glaxosmithkline Pharmaceuticals Ltd stock performing today in the market?
Glaxosmithkline Pharmaceuticals Ltd stock opened at ₹2,116 and is currently trading at ₹2,121.5, showing a gain of ₹18.30 (0.87%). The intraday high is ₹2,131.9 and low is ₹2,088.1. The trading volume stands at 3,57,494 shares, indicating moderate market participation today.
08What is the P/E ratio of Glaxosmithkline Pharmaceuticals Ltd and what does it indicate?
Glaxosmithkline Pharmaceuticals Ltd has a Price-to-Earnings (P/E) ratio of 34.67, which means investors are willing to pay ₹34.67 for every ₹1 of earnings. With an EPS of ₹61.20, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Glaxosmithkline Pharmaceuticals Ltd (GLAXO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy